SCHEMBL892804

SCHEMBL892804

CNC(=O)[C@@H](N)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6671727 1.00
SCHEMBL2568464 1.00
Hydrochloric Acid SCHEMBL4771535 0.97 DPP4 (0.50)
Hydrochloric Acid SCHEMBL19900820 0.97 DPP4 (0.50)
Trifluoroacetic Acid SCHEMBL27230994 0.85 SLC7A5 (0.43)
Trifluoroacetic Acid SCHEMBL27210261 0.85 SLC7A5 (0.43)
SCHEMBL19503059 0.84 DPP4 (0.53)
SCHEMBL19522543 0.84 DPP4 (0.53)
SCHEMBL20990277 0.82 DPP4 (0.52)
Trifluoroacetic Acid SCHEMBL27923223 0.82 DPP4 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11980669-B2 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation PFIZER, INC. (US) 2024-05-14 US claimed
CN-115819260-B Synthesis process of sitagliptin intermediate 江苏阿尔法药业股份有限公司 2024-03-19 CN claimed
CN-116137818-A Para-amino-benzyl linkers, methods of making and use thereof in conjugates 法国施维雅药厂 2023-05-19 CN claimed
CN-114845738-A Treatment with site-specific HER2 antibody-drug conjugates 辉瑞大药厂 2022-08-02 CN claimed
CN-108473591-B Site-specific HER2 antibody drug conjugates 辉瑞公司 2022-01-28 CN claimed
WO-2012143499-A2 NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-10-26 WO claimed
WO-2011149995-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-12-01 WO claimed
WO-2004026293-A2 HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS WYETH HOLDINGS CORPORATION (US) 2004-04-01 WO claimed
EP-0678503-B1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities NOVARTIS AG (CH) 1999-09-01 EP claimed
US-20250339550-A1 ANTIBODY-DRUG CONJUGATES TARGETING HUMAN CLAUDIN 18.2 LANOVA MEDICINES LTD COMPANY (CN) 2025-11-06 US disclosed
EP-4619037-A1 SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT Lerchen, Hans-Georg (DE) 2025-09-24 EP disclosed
EP-4619044-A1 ANTIBODY-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT Lerchen, Hans-Georg (DE) 2025-09-24 EP disclosed
CN-120192413-A Antibody targeting FR alpha or antibody coupling drug and application thereof 三优生物医药(上海)有限公司 2025-06-24 CN disclosed
US-20250163164-A1 ANTI-IL-13RA2 MONOCLONAL ANTIBODIES AND USES THEREOF LANOVA MEDICINES DEVELOPMENT CO., LTD. (CN) 2025-05-22 US disclosed
WO-1993009102-A1 HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1993-05-13 WO disclosed
US-5103009-A Method for the preparation of herbicidal intermediates AMERICAN CYANAMID COMPANY (US) 1992-04-07 US disclosed
EP-0304134-A2 Magnetic resin composition DSM N.V. (NL) 1989-02-22 EP disclosed
EP-0137351-B1 Process for the enantioselective préparation of acyclic alpha-alkylated alpha-aminecarboxylic acids Degussa Aktiengesellschaft (DE) 1987-03-04 EP disclosed
US-4585892-A Process for the enantioselective production of α-alkylated, acyclic α-aminocarboxylic acids DEGUSSA AKTIENGESELLSCHAFT (DE) 1986-04-29 US disclosed
EP-0137351-A2 Process for the enantioselective préparation of acyclic alpha-alkylated alpha-aminecarboxylic acids Degussa Aktiengesellschaft (DE) 1985-04-17 EP disclosed